- The impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.Am Heart J. 2011; 161: 755-763
- Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Am J Cardiol. 2006; 97: 9G-19G
- A randomized trial of therapies for type 2 diabetes and coronary artery disease.N Engl J Med. 2009; 360: 2503-2515
- Modifications of coronary risk factors.Am J Cardiol. 2006; 97: 41G-52G
US Department of Health and Human Services Agency for Health Research and Quality. National healthcare disparities report, 2004. AHRQ publication 2004;No. 05-0014. Rockville, MD: Agency for Health Research and Quality.
Centers for Disease Control and Prevention. National Vital Statistics Report. 2009;57:14, Table 17.
- Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002.Diabetes Care. 2006; 29: 1924-1925
- Front Matter.in: Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care [with CD]. The National Academies Press, Washington, DC2003
- Association of health literacy with self-management behavior in patients with diabetes.Diabetes Care. 2004; 27: 2980-2982
- Racial differences in the use of revascularization procedures after coronary angiography.JAMA. 1993; 269: 2642-2646
- Understanding racial variation in the use of coronary revascularization procedures: the role of clinical factors.Arch Intern Med. 2000; 160: 1329-1335
- Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter?.N Engl J Med. 1997; 336: 480-486
- Access to coronary artery bypass surgery by race/ethnicity and gender among patients who are appropriate for surgery.Med Care. 1999; 37: 68-77
- Does Black ethnicity influence the development of stent thrombosis in the drug-eluting stent era?.Circulation. 2010; 122: 1085-1090
- Racial difference in cardiovascular outcomes following percutaneous coronary intervention in a public health service patient population.J Invasive Cardiol. 2010; 22: 168-173
- Ethnic differences in the presentation, treatment strategy, and outcomes of percutaneous coronary intervention (a report from the national heart, lung, and blood institute dynamic registry).Am J Cardiol. 2003; 92: 773-778
- Diabetes health disparities: a systematic review of health care interventions.Med Care Res Rev. 2007; 64: 56
- Cardiovascular health disparities: a systematic review of health care interventions.Med Care Res Rev. 2007; 64: 29S-100S
- Physician performance and racial disparities in diabetes mellitus care.Arch Intern Med. 2008; 168: 1145-1151
- The effect of dietary patterns on estimated coronary heart disease risk: results from the Dietary Approaches to Stop Hypertension (DASH) trial.Circ Cardiovasc Qual Outcomes. 2010; 3: 484-489
- Actively engaging patients in treatment decision making and monitoring as a strategy to improve hypertension outcomes in diabetes mellitus.Circulation. 2008; 117: 1355-1357
- Trends in diabetes prevalence and diabetes-related complications in older Mexican Americans from 1993–1994 to 2004–2005.Diabetes Care. 2009; 32: 2212-2217
- Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program.Circulation. 2010; 121: 2294-2301
- Minding the competition: racial differences in cardiovascular risk.Circulation. 2012; 126: 8-10
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) is funded by the National Heart, Lung and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (Grants U01 HL061744 , U01 HL061746 , U01 HL061748 , U01 HL063804 ).
BARI 2D received significant supplemental funding from GlaxoSmithKline , and additional funding from Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.), Astellas Pharma US, Inc. , Merck & Co., Inc. , Abbott Laboratories, Inc. and Pfizer, Inc. Medications and supplies were donated by Abbott Laboratories Ltd., MediSense Products, Bayer Diagnostics, Becton, Dickinson and Company, J. R. Carlson Labs, Centocor, Inc., Eli Lilly and Company, LipoScience, Inc., Merck Sante, Novartis Pharmaceuticals Corporation, and Novo Nordisk, Inc.
As an National Institutes of Health (NIH)–funded trial, we are required to abide by the NIH PubMed Central Policy that we retain the right to provide a copy of the final manuscript to the NIH upon acceptance for publication by your journal, for public archiving in PubMed Central as soon as possible, but no later than 12 months after publication.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute, the National Institute of Diabetes And Digestive And Kidney Diseases, or the National Institutes of Health.
See page 1304 for disclosure information.